Arai Y, Yoshiki T, Okada K, Yoshida O
Department of Urology, Faculty of Medicine, Kyoto University, Japan.
Urol Int. 1989;44(3):135-40. doi: 10.1159/000281489.
Serum prostatic specific antigen (PA), gamma-seminoprotein (gamma-Sm) and prostatic acid phosphatase (PAP) were evaluated in 141 patients with prostatic cancer, 121 of whom were newly diagnosed. Of the 121 untreated patients, 77, 71 and 67% were detectable by the PA, gamma-Sm and PAP markers, respectively. PA was equally or more sensitive in all stages than the other two markers. Using the benign prostatic hypertrophy group (131 patients) as a negative control, the specificities of PA, gamma-Sm and PAP were 89, 76 and 83%, respectively. Combination of PA, gamma-Sm and PAP increased sensitivity to 86%, especially in localized disease (stages A, B and C) to 74%, but did not improve specificity (67%) or efficiency (76%). During the follow-up period of 1-53 months, 24 of 141 patients with prostatic cancer had disease progression. All serial levels of gamma-Sm, PA, and PAP were positive in 17, 12 and 10 of the 24 patients within 6 months prior to detectable disease progression. gamma-Sm appeared to be more sensitive than the other two markers for early detection of disease progression. These results suggest that PA and gamma-Sm are reliable markers for detection and monitoring of prostatic cancer.
对141例前列腺癌患者的血清前列腺特异性抗原（PA）、γ-精浆蛋白（γ-Sm）和前列腺酸性磷酸酶（PAP）进行了评估，其中121例为新诊断患者。在121例未经治疗的患者中，PA、γ-Sm和PAP标志物的可检测率分别为77%、71%和67%。在所有分期中，PA的敏感性与其他两种标志物相当或更高。以良性前列腺增生组（131例患者）作为阴性对照，PA、γ-Sm和PAP的特异性分别为89%、76%和83%。PA、γ-Sm和PAP联合使用可将敏感性提高到86%，尤其是在局限性疾病（A、B和C期）中提高到74%，但特异性（67%）和效率（76%）并未提高。在1至53个月的随访期内，141例前列腺癌患者中有24例病情进展。在可检测到疾病进展前6个月内，24例患者中有17例、12例和10例的γ-Sm、PA和PAP的所有连续水平均为阳性。γ-Sm似乎比其他两种标志物对疾病进展的早期检测更敏感。这些结果表明，PA和γ-Sm是检测和监测前列腺癌的可靠标志物。
